Q-omics provides the consensus-scored TIGD2 profile across patient tissues and cancer cell-line models. TIGD2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TIGD2 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, TIGD2 RNA expression shows 19,524 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where TIGD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIGD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIGD2 survival associations across molecular data types. TIGD2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIGD2 RNA expression–survival associations across cancer types. High TIGD2 expression shows unfavorable associations in KICH, MESO and PAAD, but favorable associations in KIRC, READ and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TIGD2 RNA expression.
This table summarizes TIGD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TIGD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIGD2 shows higher tumor expression in BLCA, LUAD, HNSC, UCEC, COAD and STAD. The BLCA box plot shows higher TIGD2 RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with TIGD2 in patient tissues and cancer cell lines. In patient samples, TIGD2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIGD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
